DDrare: Database of Drug Development for Rare Diseases

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AVASTIN; AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung; Acetate; Avastin; BEVACIZUMAB; Bevacizumab; Bevacuzimab spray; Blood samples; Chloride; Dicynone; Doxycycline; Doxycycline Hyclate; EMEA/H/C/000712; ETAMSYLATE; Estriol; Etamsylate; Ferrous sulphate 200mg oral tablet; Floseal; Gold; Itraconazole; Mupirocin; NINTEDANIB; NaCl; Nintedanib; Nintédanib; OCTREOTIDE; OCTREOTIDE ACETATE; OFEV; Octreotide; Octreotide LAR; Other: Epistaxis charts; Other: Packing; Other: Standard Treatment; Other: Standard care; PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung; Pazopanib; Pegylated Interferon Alpha2b; Pomalidomide; Pomalidomide Oral Product; Propranolol; Propranolol treatment; RVG 18236; Ranibizumab; SODIUM CHLORIDE; SUB16402MIG; Sandostatin LAR; Sandostatin LAR 20 mg; Sclerotherapy; Sodium chloride; Soy protein isolate; Sporanox; Sterile saline; Submucosal Bevacizumab; THALIDOMIDE; THALIDOMIDE CELGENE*28CPS 50MG; TIMOLOL MALEATE; Tacrolimus; Tacrolimus (Advagraf); Tacrolimus capsule (low-dose); Tamoxifen; Thalidomide; Timolol; Timolol Alcon 0.5% collyre; Timolol Gel; Timolol nasal spray; Topical timolol maleate; Tranexamic Acid; Tranexamic acid; Vit D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03910244 (ClinicalTrials.gov)	October 17, 2019	8/4/2019	Pomalidomide for the Treatment of Bleeding in HHT	Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia	Telangiectasia, Hereditary Hemorrhagic	Drug: Pomalidomide Oral Product;Drug: Placebo oral capsule	The Cleveland Clinic	RTI International	Active, not recruiting	18 Years	99 Years	All	2	Phase 2	United States
2	NCT02287558 (ClinicalTrials.gov)	January 27, 2015	6/11/2014	Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study	A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia	Hereditary Hemorrhagic Telangiectasia;Idiopathic Vascular Ectasia	Drug: Pomalidomide	The Cleveland Clinic	NULL	Completed	18 Years	N/A	All	9	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03910244
(ClinicalTrials.gov)

October 17, 2019

8/4/2019

Pomalidomide for the Treatment of Bleeding in HHT

Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia

Telangiectasia, Hereditary Hemorrhagic

Drug: Pomalidomide Oral Product;Drug: Placebo oral capsule

The Cleveland Clinic

RTI International

Active, not recruiting

18 Years

99 Years

All

Phase 2

United States

NCT02287558
(ClinicalTrials.gov)

January 27, 2015

6/11/2014

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study

A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia

Hereditary Hemorrhagic Telangiectasia;Idiopathic Vascular Ectasia

Drug: Pomalidomide

The Cleveland Clinic

NULL

Completed

18 Years

N/A

All

Phase 1

United States